PMID- 34582968
OWN - NLM
STAT- MEDLINE
DCOM- 20220217
LR  - 20220217
IS  - 1878-5492 (Electronic)
IS  - 0966-3274 (Linking)
VI  - 69
DP  - 2021 Dec
TI  - A descriptive analysis of non-human leukocyte antigens present in renal 
      transplant donor-recipient pairs.
PG  - 101474
LID - S0966-3274(21)00114-3 [pii]
LID - 10.1016/j.trim.2021.101474 [doi]
AB  - INTRODUCTION: End stage renal disease (ESRD) is the irreversible deterioration of 
      renal function requiring renal replacement therapy by dialysis or transplant. 
      Human leucocyte antigens (HLA) have been well examined however research still is 
      required into the non-HLA antibodies. Antibody mediated rejection (AMR) can be 
      seen in the absence of HLA antibodies on biopsies of patients who have received 
      identical transplants; anti-endothelial cell antibodies may explain this. 
      Investigation into endothelial cell antigens on donor and recipient endothelium 
      may elucidate and stratify the degree of risk of any given transplant and may 
      guide towards the best matched donor. METHODS: Protein array analysis was carried 
      out on 8 patient pairs using nitro-cellulose membranes and biotinylated detection 
      antibodies. The fluorescence emitted was captured by X-Ray film and results were 
      recorded with ImageJ software. A fold increase of more than 2 was considered to 
      be positive. RESULTS: 11 proteins identified had a fold increase of increase >/=2 
      and were present in >/=2 patient pairs which may point to potential clinical 
      utility. Nectin2/CD112 may be measured in order analyse graft survival time in 
      transplant recipients. Prognosticating renal failure has clinical importance and 
      potential markers that have been identified to aid which include MEPE, CRELD2, 
      and TIMP-4. Novel pharmacological therapies for specific biomarkers identified in 
      this study include JAM-A, E-Selectin, CD147, Galectin-3, JAM-C, PAR-1, and TNFR2. 
      CONCLUSION: Protein analysis showed differences in expression of antigens between 
      patients with and without Chronic Kidney Disease (CKD). This information could be 
      used at the matching stage of renal transplantation and also in the treatment of 
      rejection episodes. The results highlight biomarkers that potentially 
      prognosticate and pharmacological therapies that may ameliorate kidney disease 
      and rejection in ESRD and transplant recipients.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Sisk, Louis J
AU  - Sisk LJ
AD  - University of Glasgow, United Kingdom; British Heart Foundation Cardiovascular 
      Research Centre, University of Glasgow, United Kingdom. Electronic address: 
      louisjsisk@gmail.com.
FAU - Patel, Rajan K
AU  - Patel RK
AD  - University of Glasgow, United Kingdom; British Heart Foundation Cardiovascular 
      Research Centre, University of Glasgow, United Kingdom.
FAU - Stevens, Kathryn K
AU  - Stevens KK
AD  - University of Glasgow, United Kingdom; British Heart Foundation Cardiovascular 
      Research Centre, University of Glasgow, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20210925
PL  - Netherlands
TA  - Transpl Immunol
JT  - Transplant immunology
JID - 9309923
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Graft Rejection
MH  - Graft Survival
MH  - HLA Antigens
MH  - Humans
MH  - Kidney/physiology
MH  - *Kidney Transplantation
MH  - Renal Dialysis
MH  - Transplant Recipients
OTO - NOTNLM
OT  - Animals
OT  - Atherosclerosis
OT  - Biomarkers
OT  - CD112
OT  - CD147
OT  - CKD
OT  - CRELD2
OT  - Chronic Kidney Disease
OT  - Complications
OT  - Diabetic
OT  - Disease progression
OT  - Donors
OT  - Dysfunction
OT  - EMMPRIN
OT  - ESRD
OT  - ESelectin
OT  - End stage renal disease
OT  - FGF-23
OT  - Female
OT  - Galectin-3
OT  - Glomerulosclerosis
OT  - Humans
OT  - Hypertension
OT  - Inflammation
OT  - JAM-A
OT  - JAM-C
OT  - Kidney
OT  - Kidney failure
OT  - MEPE
OT  - Male
OT  - Mediators
OT  - Metabolism
OT  - Nectin-2
OT  - Nephropathy
OT  - Novel
OT  - PAR-1
OT  - Pharmacological
OT  - Protein array analysis
OT  - Receptors
OT  - Recipients
OT  - Rejection
OT  - Renal
OT  - TIMP-4
OT  - TNFR2
OT  - TNFRSF1b
OT  - Therapy
OT  - Transplant
OT  - Tumour necrosis factor
EDAT- 2021/09/29 06:00
MHDA- 2022/02/19 06:00
CRDT- 2021/09/28 20:16
PHST- 2021/07/31 00:00 [received]
PHST- 2021/09/22 00:00 [revised]
PHST- 2021/09/22 00:00 [accepted]
PHST- 2021/09/29 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
PHST- 2021/09/28 20:16 [entrez]
AID - S0966-3274(21)00114-3 [pii]
AID - 10.1016/j.trim.2021.101474 [doi]
PST - ppublish
SO  - Transpl Immunol. 2021 Dec;69:101474. doi: 10.1016/j.trim.2021.101474. Epub 2021 
      Sep 25.